Context Therapeutics receives Nasdaq extension until Feb 23, 2026 for bid price compliance

Context Therapeutics Inc.

Received Nasdaq extension letter on Aug 28, 2025; new compliance deadline Feb 23, 2026.
Originally notified of non-compliance on Feb 27, 2025; need $1.00 closing bid for 30 consecutive days.
Company may consider reverse stock split to regain bid price compliance.
Listing and trading of CNTX common stock unaffected by extension letter.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.